BeneVir Granted Patent Protecting Lead Oncolytic Immunotherapy Stealth-1H and Other Platform Assets – Yahoo Finance
|
BeneVir Granted Patent Protecting Lead Oncolytic Immunotherapy Stealth-1H and Other Platform Assets
Yahoo Finance 9,623,059, entitled “Oncolytic Herpes Simplex Virus and Therapeutic Uses Thereof”, covering the composition of matter for Stealth-1H, BeneVir's lead oncolytic immunotherapy, as well as other platform assets. BeneVir is a portfolio company within … |
